Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
POXEL - CORPORATE | EUR14(+99%) Poxel serenely progresses on the road to success Twymeeg (imeglimin) approved in Japan On the good way to confirm Phase II data for PXL 770 in NASH Making PXL065 the second success in NASH A need for additional cash in 2022 A valuation which underestimates NASH assets
POXEL - CORPORATE | EUR14.8 VS. 14(+97%) Major milestone as Twymeeg is approved in Japan Imeglimine, now called Twymeeg, approved in Japan From Japan to all Asia ? A total of up to USD230m of milestones and royalties still to receive Minor adjustment to our TP
Poxel is a biotechnology company created in 2009 with assets and scientists from Merck Serono. It focuses on the treatment of metabolic diseases, particularly diabetes and NASH. Its originality lies in its main target, the mitochondrion. The latter is an important player in the homeostasis of glucose and fats by regulating the energy needs of our cells.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.